Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns.

In terms of endpoints for the treatment of fibrotic pulmonary sarcoidosis, improvements in pulmonary function and functional status/QOL from anti-granulomatous therapy may be significant yet are unlikely to be large because improvement in the patient’s pulmonary function is unlikely to be great 57 .

also in 13,097 other papers